Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
72,922,597
-
Total 13F shares
-
28,007,948
-
Share change
-
-1,516,895
-
Total reported value
-
$99,997,228
-
Put/Call ratio
-
25100%
-
Price per share
-
$3.47
-
Number of holders
-
88
-
Value change
-
-$11,520,761
-
Number of buys
-
40
-
Number of sells
-
40
Institutional Holders of Lexeo Therapeutics, Inc. - Common Stock (LXEO) as of Q1 2025
As of 31 Mar 2025,
Lexeo Therapeutics, Inc. - Common Stock (LXEO) was held by
88 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,007,948 shares.
The largest 10 holders included
JANUS HENDERSON GROUP PLC, CITADEL ADVISORS LLC, BlackRock, Inc., Affinity Asset Advisors, LLC, Omega Fund Management, LLC, Blackstone Inc., Vestal Point Capital, LP, Novo Holdings A/S, VANGUARD GROUP INC, and Point72 Asset Management, L.P..
This page lists
88
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.